Increased knowledge regarding the prognostic impact of genetic mutations on survival is changing therapeutic decision-making for patients with AML in first complete remission (CR1). Research on disease status and the timing of therapy has shown a significant impact on patient outcomes. Presenters use an interactive, case study-based format to identify patient- and disease-specific factors used to assess the risks and benefits of post-induction therapy, including hematopoietic cell transplantation (HCT) versus non-transplant therapies.

ACCME Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and National Marrow Donor Program. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement:

The Medical College of Wisconsin designates this Enduring Material for a maximum of 1 AMA PRA Category 1 Credit(s) ™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 1 hours of participation for continuing education for allied health professionals.  

Questions?

If you have any questions regarding this activity, contact Nicole Heino, continuing education manager, Education and Training, NMDP/Be The Match at (800) 526-7809 ext. 4811, or email [email protected].

This webinar series is sponsored by NMDP/Be The Match and partially funded through a National Comprehensive Cancer Network education intervention grant. For information on the study, contact Ellen Denzen, M.S., Health Services Research, NMDP/Be The Match at [email protected].